诺华

最新新闻

• 评级变动
  Morgan Stanley Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $170
  \u5e02\u573a\u8d44\u8baf · 2026/3/26
• 评级变动
  TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Raises Target Price to $180
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  Bernstein Initiates Novartis AG(NVS.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/3/20
• BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $180
  \u5e02\u573a\u8d44\u8baf · 2026/3/11
• 评级变动
  HSBC Maintains Novartis AG(NVS.US) With Sell Rating, Raises Target Price to $112
  \u5e02\u573a\u8d44\u8baf · 2025/12/10
• 评级变动
  BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $177.37
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  Barclays Initiates Novartis AG(NVS.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/1/7
• BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $185.56
  \u5e02\u573a\u8d44\u8baf · 2026/9/7
• Morgan Stanley Maintains Novartis AG(NVS.US) With Buy Rating, Cuts Target Price to $156
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Cuts Target Price to $175.32
  \u5e02\u573a\u8d44\u8baf · 2026/3/27
• 公司公告
  SAAG CONSOLIDATED (M): Britac Berhad Disposal of 350,000 shares of HK$1.00 each representing 70% of the total issued and paid up share capital of Britac (China) Limited by Britac-Saag (S) Pte Ltd, a wholly owned subsidiary of Britac Berhad to NVS Invest &
  Bursa Malaysia · 2003/4/22
• TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $180
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $160
  \u5e02\u573a\u8d44\u8baf · 2026/6/6
• 公司公告
  SAAG CONSOLIDATED (M): Britac Berhad ("Britac") - Disposal of 350,000 shares of HK$1.00 each representing 70% of the total issued and paid up share capital of Britac (China) Limited by Britac-Saag (S) Pte Ltd, a wholly owned subsidiary of Britac to NVS
  Bursa Malaysia · 2003/4/17
• 评级变动
  Morgan Stanley Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $143
  \u5e02\u573a\u8d44\u8baf · 2025/12/3
• 评级变动
  BofA Securities Upgrades Novartis AG(NVS.US) to Buy Rating, Raises Target Price to $177.65
  \u5e02\u573a\u8d44\u8baf · 2026/3/23
• BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Announces Target Price $172.96
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  J.P. Morgan Initiates Novartis AG(NVS.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2025/11/21
• 评级变动
  BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Cuts Target Price to $177.61
  \u5e02\u573a\u8d44\u8baf · 2026/3/24
• Novartis AG (NVS.US) secures approval in China for a new indication for its blockbuster radiopharmaceutical
  Zhitong Finance · 2026/8/26
• Setback for the second time in a week! Novartis (NVS.US) sees its blockbuster heart disease drug fail in Phase III trials, causing a sharp drop in share price; Amgen (AMGN.US) suffers collateral damage.
  Zhitong Finance · 2026/9/7
• 评级变动
  BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $180
  \u5e02\u573a\u8d44\u8baf · 7/27
• Strong sales of innovative drugs offset the impact from generics! Novartis AG (NVS.US) Q2 results beat expectations, signaling a return to growth trajectory.
  Zhitong Finance · 7/21

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。